Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.27), $0.06 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $118.46 million versus the consensus estimate of $119.99 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.